Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): A single-institution study

Pediatric Hematology and Oncology

Volumn 23, Issue 3, 2006, Pages 207-216

  Ruud, Ellen ^a   Holmstrøm, Henrik ^a   De Lange, Charlotte ^a   Natvig, Solveig ^a   Albertsen, Birgitte ^b   Wesenberg, Finn ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute lymphoblastic leukemia; Antithrombin; Asparaginase; Thrombosis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBIN; ASPARAGINASE; BACTERIAL ENZYME; BLOOD CLOTTING INHIBITOR; ESCHERICHIA COLI ASPARAGINASE; PROTEIN C; PROTEIN S; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVICE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMAN; LIVER TOXICITY; MALE; NOPHO ACUTE LYMPHOBLASTIC LEUKEMIA 1992 PROTOCOL; NOPHO ACUTE LYMPHOBLASTIC LEUKEMIA 2000 PROTOCOL; PROTEIN DETERMINATION; THROMBOGENICITY; THROMBOSIS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITHROMBINS; ASPARAGINASE; CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMANS; INFANT; JUGULAR VEINS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PROTEIN C; PROTEIN S; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33644834925     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010500506701     Document Type: Article

References (28)

1. Kidd JG. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum - course of transplanted cancers of various kinds in mice and rats given guinea pig serum or rabbit serum. J Exp Med. 1953;98:565-582.
2. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects and properties of the L-asparaginase of guinea pig serum and yeast in relation to those of the the antilymphoma substance. J Exp Med. 1963;118:99-120.
3. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28:97-113.
4. Priest JR, Ramsay NK, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100:984-989.
5. Priest JR, Ramsay NK, Bennett AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 1982;100:990-995.
6. Andrew M, Monagle PT, Brooker L. Thromboemblic Complications During Infancy and Childhood. Hamilton, London: BC Decker; 2000.
7. Ruud E, Holmstrom H, Natvig S, Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer: a prospective study. Med Pediatr Oncol. 2002;38:405-410.
8. Gatta G, Corazziari I, Magnani C, Peris-Bonet R, Roazzi P, Stiller C. Childhood cancer survival in Europe. Ann Oncol. 2003;14(Suppl 5):v119-v127.
9. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia. 2000;14:2267-2275.
10. Pinheiro JP, Boos J. The best way to use asparaginase in childhood acute lymphatic leukaemia - still to be defined? [Review] [69 refs]. Br J Haematol. 2004;125:117-127.
11. Albertsen BK, Schroder H, Jakobsen P, Muller HJ, Carlsen NT, Schmiegelow K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clini Pharmacol. 2001;52:433-437.
12. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32A:1544-1550.
13. Asselin BL. The three asparaginases: comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621-629.
14. Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol. 1990;18:497-502.
15. Alberts SR, Bretscher M, Wiltsie JC, O'Neill BP, Mokri B, Witzig TE. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leuk Lymphoma. 1999;32:489-496.
16. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res. 2001;103:165-172.
17. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood. 1994;83:386-391.
18. Nowak-Gottl U, Werber G, Ziemann D, Ahlke E, Boos J. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica. 1996;81:127-131.
19. De Cicco M, Matovic M, Balestreri L, et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res. 1997;86:101-113.
20. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665-3675.
21. Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. [Review] [82 refs]. Blood Coagul Fibrinolysis. 1994;5(Suppl):36.
22. Nowak-Gottl U, Boos J, Wolff JE. et al. Asparaginase decreases clotting factors in vitro: a possible pitfall? Int J Clini Lab Res. 1995;25:146-148.
23. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97:508-516.
24. Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2004;18:1072-1077.
25. Nowak-Gottl U, Ahlke E, Schulze-Westhoff P, Boos J. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol. 1996;95:123-126.
26. Nowak-Gottl U, Rath B, Binder M, et al. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. [Comment] Haematologica. 1995;80:451-453.
27. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia: results of the PARKAA study. Thromb Haemost. 2003;90:235-244.
28. Male C, Chait P, Ginsberg J, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children. Thromb Haemost. 2002;87:593-598.